The primary mechanism of Ibrance is to inhibit the activity of CDK4/6 proteins. By doing so, it helps to halt the proliferation of cancer cells. Specifically, it is used in combination with hormone therapy (such as letrozole or fulvestrant) to treat hormone receptor-positive, HER2-negative breast cancer. This combination is particularly effective in postmenopausal women.
